MYLAXEN Drug Patent Profile
✉ Email this page to a colleague
When do Mylaxen patents expire, and when can generic versions of Mylaxen launch?
Mylaxen is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.
The generic ingredient in MYLAXEN is hexafluorenium bromide. There is one drug master file entry for this compound. Additional details are available on the hexafluorenium bromide profile page.
Summary for MYLAXEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Patent Applications: | 755 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MYLAXEN at DailyMed |
US Patents and Regulatory Information for MYLAXEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medpointe Pharm Hlc | MYLAXEN | hexafluorenium bromide | INJECTABLE;INJECTION | 009789-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |